—
C+
C+ The full Closelooknet — membership. Open the C+ overview

LAKEFRONT BIOTHERAPEUTICS NV (LKFT.AS) — chart, structure and Closelooknet read

The Closelooknet read

Lakefront Biotherapeutics develops medicines for oncology and immunology in the United States and Europe. Its pipeline includes GLPG3667, in a phase 2 trial for dermatomyositis and lupus, and two CAR-T candidates, GLPG5101 and GLPG5301, made at the point of care and tested in phase 1/2 trials for lymphoma and myeloma.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for LKFT.AS, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 45/100 · S&P 500 fund at 49, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-03
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 76th percentile of the window, -20.6% over 20 sessions. Factor regime → 2026-11-02
  • Sector × region Health care in Europe: +2.6% week · +14.4% month · +9.0% quarter · +8.2% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-03
  • Sovereign pressure Index -1.63 · down 2.22 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-02
Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against LKFT.AS on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — LAKEFRONT BIOTHERAPEUTICS NV

LKFT.AS in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Lakefront Biotherapeutics develops medicines for oncology and immunology in the United States and Europe. Its pipeline includes GLPG3667, in a phase 2 trial for dermatomyositis and lupus, and two CAR-T candidates, GLPG5101 and GLPG5301, made at the point of care and tested in phase 1/2 trials for lymphoma and myeloma. The company works with Gilead Sciences under a collaboration agreement and is based in Mechelen, Belgium, having taken its current name after operating as Galapagos.
Where it sits in the stack
Lakefront carries no seat in our index; it belongs to the healthcare sleeve of our universe, under the biotechnology industry, where the diary tracks clinical-stage drug and cell-therapy developers rather than build-out infrastructure.
Who it is priced against
Closelooknet's peer group for this name is not yet defined; the market compares it with other point-of-care CAR-T developers such as Legend Biotech, and it already has a working collaboration with Gilead Sciences.
Why Closelooknet tracks it
Lakefront holds no seat in our indices and has not yet built a Closelooknet score; it does not appear in any edition or quoted note in the diary.
What the diary watches
Whether the point-of-care manufacturing for its CAR-T candidates scales beyond early trials, and whether the collaboration with Gilead widens or narrows the pipeline it pursues alone.

LAKEFRONT BIOTHERAPEUTICS NV (LKFT.AS) trades on the AS exchange in Netherlands, classified under Healthcare.

The Closelooknet company score reads 56/100 composite (momentum 78, quality 68, valuation 35) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What LKFT.AS pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count −0.0% in FY2025 24 m EUR of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-04

Quick answers

What is LAKEFRONT BIOTHERAPEUTICS NV (LKFT.AS)?

LAKEFRONT BIOTHERAPEUTICS NV trades as LKFT.AS on the AS exchange (Netherlands) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-04.

Is LKFT.AS in a Closelooknet index?

Not currently — LAKEFRONT BIOTHERAPEUTICS NV is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-04.

What is LAKEFRONT BIOTHERAPEUTICS NV's Closelooknet composite score?

56 out of 100, with momentum 78, quality 68 and valuation 35 sub-scores, as of 2026-11-04. Scores are Closelooknet's own research readings, not ratings or investment advice.

What does LAKEFRONT BIOTHERAPEUTICS NV do?

Lakefront Biotherapeutics develops medicines for oncology and immunology in the United States and Europe. Its pipeline includes GLPG3667, in a phase 2 trial for dermatomyositis and lupus, and two CAR-T candidates, GLPG5101 and GLPG5301, made at the point of care and tested in phase 1/2 trials for lymphoma and myeloma. The company works with Gilead Sciences under a collaboration agreement and is based in Mechelen, Belgium, having taken its current name after operating as Galapagos. Closelooknet's peer group for this name is not yet defined; the market compares it with other point-of-care CAR-T developers such as Legend Biotech, and it already has a working collaboration with Gilead Sciences. (Company snapshot of 2026-09-17.)

Where does LAKEFRONT BIOTHERAPEUTICS NV sit in the AI build-out?

Lakefront carries no seat in our index; it belongs to the healthcare sleeve of our universe, under the biotechnology industry, where the diary tracks clinical-stage drug and cell-therapy developers rather than build-out infrastructure. Lakefront holds no seat in our indices and has not yet built a Closelooknet score; it does not appear in any edition or quoted note in the diary. (Company snapshot of 2026-09-17.)

Does LAKEFRONT BIOTHERAPEUTICS NV pay a dividend?

No cash distribution shows in LAKEFRONT BIOTHERAPEUTICS NV’s price series over the last three years. The share count fell 0.0% over the fiscal year. As of 2026-11-03; the "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for LKFT.AS, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.